Generic Health Pty Ltd v Otsuka Pharmaceutical Co., Ltd

Link copied
Case Copied 77 min read

FEDERAL COURT OF AUSTRALIA

Generic Health Pty Ltd v Otsuka Pharmaceutical Co., Ltd [2013] FCAFC 17

Citation: Generic Health Pty Ltd v Otsuka Pharmaceutical Co., Ltd [2013] FCAFC 17
Appeal from: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2012] FCA 239
Parties: GENERIC HEALTH PTY LTD (ACN 110 617 859) v OTSUKA PHARMACEUTICAL CO., LTD and BRISTOL-MYERS SQUIBB COMPANY
File number: NSD 490 of 2012
Judges: EMMETT, BENNETT AND GREENWOOD JJ
Date of judgment: 6 March 2013
Addendum: 8 March 2013
Catchwords:

PATENTS – s 117(2)(b) of the Patents Act 1990 (Cth) – whether supplier of product, which was not a staple commercial product, had reason to believe that the person to whom product supplied would put the product to an infringing use

PATENTS – appeal against interlocutory injunction – threatened supply of generic pharmaceutical products – whether prima facie case of infringement – whether prima facie case in a Beecham sense – whether assessment or evaluation of strength of prima facie case required –  whether balance of convenience and justice favours the grant of interlocutory injunctive relief

Legislation: Patents Act 1990 (Cth) ss 117(1), 117(2)(a), 117(2)(b), 117(2)(c)
Patents Act 1977 (UK) ss 60(2), 60(3)
Patent Act 1952 (US)
Cases cited: Apple Inc v Samsung Electronics Co Limited [2011] HCA Trans 341
Australian Broadcasting Corporation v O’Neill (2006) 227 CLR 57
Aktiebolaget Hassle v Alphapharm Pty Limited (2002) 212 CLR 411
Apotex Pty Ltd v Sanofi-Aventis Australia Pty Limited (No 2) (2012) 204 FCR 494
Australian Coal and Shale Employees’ Federation v The Commonwealth (1953) 94 CLR 621
BeechamGroup Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618
Collins v Northern Territory (2007) 161 FCR 549
Grimme Landmaschinenfabrik GmbH & Co KG v Scott [2010] EWCA Civ 1110; (2010) 89 IPR 631
Jackson v Sterling (1987) 162 CLR 612
Jonker v Platform Solutions Pty Limited [2012] FCA 237
KCI Licensing v Smith & Nephew Plc [2010] EWCA Civ 1260; [2010] All ER (D) 203 (Nov).
KCI Licensing v Smith & Nephew Plc [2010] EWHC 1487 (Pat); [2010] FSR 740
Northern Territory v Collins (2008) 235 CLR 619
Samsung Electronics Co Limited v Apple Inc (2011) 286 ALR 257
Sigma Pharmaceuticals (Australia) Pty Limited v Wyeth (2009) 81 IPR 339
Date of hearing: 30 July 2012
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 263
Counsel for the applicant: AH Bowne SC with ADB Fox
Solicitor for the applicant: Middletons
Counsel for the respondents: AJ Bannon SC with C Cochrane
Solicitor for the respondents: Allens

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 490 of 2012

ON APPEAL FROM THE FEDERAL COURT OF AUSTRALIA
BETWEEN:

GENERIC HEALTH PTY LTD (ACN 110 617 859)
Applicant

AND:

OTSUKA PHARMACEUTICAL CO., LTD
First Respondent

BRISTOL-MYERS SQUIBB COMPANY
Second Respondent

JUDGE:

GREENWOOD J

DATE:

8 MARCH 2013

PLACE:

BRISBANE

ADDENDUM TO REASONS FOR JUDGMENT OF JUSTICE GREENWOOD

  1. In my reasons for judgment published on 6 March 2013, together with the reasons for judgment…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Generic Health Pty Ltd v Otsuka Pharmaceutical Co., Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2013] FCAFC 17
Decision Date

CaseChat Overview and Summary

The Federal Court of Australia was asked to decide whether an interlocutory injunction should be granted in a patent infringement case between Otsuka Pharmaceutical Co., Ltd and Generic Health Pty Ltd. Otsuka, the patent holder, sought relief on the basis that Generic Health's intended sale of generic pharmaceutical products would infringe their patents for a carbostyril compound, aripiprazole, used in the treatment of schizophrenia and other disorders of the central nervous system. Generic Health cross-claimed for the revocation of Otsuka's patents. The primary judge found a prima facie case of infringement under section 117(2)(b) of the Patents Act 1990 (Cth) and granted an interlocutory injunction against Generic Health's supply of the products. Generic Health appealed the grant of this injunction, arguing that there was insufficient evidence to establish a prima facie case of infringement and that the balance of convenience did not favour the grant of the injunction.

The court considered the nature of the products supplied and the requisite knowledge for an infringement under section 117(2)(b) of the Act. It noted that the products were not staple commercial products and that the issue of whether they were such products was not necessary to decide. The court found that there was a prima facie case that Generic Health had reason to believe that the products would be put to an infringing use, based on the evidence of the use of aripiprazole to treat cognitive impairment associated with schizophrenia. The court also held that an assessment of the strength of the prima facie case was not required under Beecham Group Ltd v Bristol Laboratories Pty Ltd and that the balance of convenience and justice favoured the grant of interlocutory injunctive relief. The court concluded that the appeal against the interlocutory injunction should be refused, and the applicant should pay the respondent’s costs.

Orders

Orders of the court

1. Leave to appeal be refused.

2. The applicant pay the respondent’s costs of the application for leave.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

The complaint as to the terms of the injunction ignores the clear language of s 117. If the prerequisites specified in s 117 are satisfied in relation to the Patent, any supply of a product by one person to another is an infringement of the Patent. The order made by the primary judge does not go beyond the language of s 117. There is insufficient doubt as to whether the prerequisites were satisfied, at least on a prima facie basis, to warrant the grant of leave to appeal on that ground. CONCLUSION The application for leave to appeal should be refused with costs. Otsuka Pharmaceutical Co., Ltd (Otsuka) is the patentee of Australian Patent No 2005201772, titled ‘Substituted carbostyril derivatives as 5-HT1A receptor sub-type agonists’ (the 772 Patent) and Australian Patent No 2002226752 with the same title (the 752 Patent). The 772 Patent was a divisional application of the complete application for the 752 Patent. Both patents claim a priority date of 29 January 2001 and claim the use of a carbostyril compound (relevantly, aripiprazole) for the production of a medicament having certain features and a method for treating a patient involving the use of aripiprazole. Aripiprazole is used for the treatment of schizophrenia and other disorders of the central nervous system said to be associated with the 5-HT1A receptor. A packaged tablet formulation containing aripiprazole is marketed by Bristol-Myers Squibb Company, by its Australian subsidiary, under licence from Otsuka under the name “Abilify”. A number of Abilify products are registered on the Australian Register of Therapeutic Goods (the ARTG) and are indicated for three treatments, including, relevantly, for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. Generic Health Pty Ltd (Generic Health) has obtained registration of a number of aripiprazole products on the ARTG. The products that are registered under the ARIPIPRAZOLE GH label (the GH Products) are registered for the first of the three indications for which the Abilify products are registered, that is, the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. Otsuka sought interim relief on the basis that Generic Health’s intended sale of the GH Products would infringe claims 1 and 7 of the 772 Patent and claims 1 to 3 and 8 to 10 of the 752 Patent. Generic Health cross-claimed seeking revocation of both patents. The primary judge found that there was a prima facie case that claim 7 of the 772 Patent would be infringed by the proposed supply by Generic Health of the GH Products. His Honour found that there was a prima facie case that the sale of GH Products would constitute infringement of claim 7 under s 117(1) of the Patents Act 1990 (Cth) (the Act), based on s 117(2)(b) of the Act. Generic Health seeks leave to appeal from the grant of an interlocutory injunction which is in the following terms:Until further order of the Court, the Respondent by itself, its directors, officers, servants and agents or otherwise be restrained from engaging in the following acts in Australia without the licence or authority of the First Applicant:(a)offering to sell or otherwise dispose of the [GH Products]; (b) importing the GH Products;(c)keeping the GH Products for the purpose of doing any of the acts described in sub-paragraphs 1(a) and 1(b) above;(d)authorising other people to engage in any of the acts described in sub-paragraphs 1(a) to 1(c) above.

Ratio Decidendi

Legal Principle Established

His Honour considered the question of “staple commercial product” and said (at [93]) that the approach contended for by Otsuka was ‘open on the present evidence’. His Honour said that it was not necessary to express a final view on whether the GH Products were, or were not, staple commercial products and declined to do so, but said that it was sufficient to be satisfied that there was a prima facie case that the GH Products were not staple commercial products. ConsiderationSubmissions on prima facie case Generic Health submits that the primary judge gave no basis for his conclusion that there was, objectively, a reason to believe on its part that the GH Products would be put to an infringing use. Generic Health says that that there was no evidence of knowledge on its part of the use to which the GH Products would be put. None of the evidence cited by the primary judge related to actual knowledge on the part of Generic Health of the matters arising from the evidence of Professor Singh and Professor McGorry. Generic Health says that the case presented by Otsuka rises no higher than there being a prospect that clinicians may switch a patient in the manner disclosed in claim 7. It also points out that there is no evidence that the GH Products will be used in a method of treatment that has all of the integers of claim 7. That is, it submits, there are also no objective criteria by which a finding that it had reason to believe that its products would be used in the method of claim 7 can be supported. There was no product information or other direction from Generic Health instructing that the GH Products be used for the infringing use. Generic Health relies upon the finding of the primary judge at [103] that there was no evidence that would enable him to conclude, with any reasonable level of confidence, that prescribing doctors would read into the Generic Health product information an instruction that the GH Products are to be used or can be used in the method of treatment specifically claimed in claim 7. The product information did not give that instruction expressly or impliedly. Accordingly, s 117(2)(c) did not apply. Generic Health relies on this finding as antithetical to a conclusion that s 117(2)(b) applies, saying that the evidence did not rise above there being a prospect of a ‘switch’ being made. This is not a case where the supplier has provided instructions or directions for an infringing use (cf Apotex v Sanofi-Aventis). For the purposes of this appeal, it is not contended that the product supplied is a staple commercial product (cf Collins (HC)). The question is whether the supply of aripiprazole to treating doctors, who then prescribe it, is an infringement of s 117(2)(b). There is no present suggestion that Generic Health had actual knowledge that the product would be put to an infringing use. The primary judge explained the use to which at least some doctors would put the product, to treat not only schizophrenia but also the cognitive impairment with which the forms of schizophrenia are associated. This arises, at least, from the use of aripiprazole as a second generation treatment of schizophrenia.